Benitec Biopharma reports 100% response rate, durable enhancements in BB-301 OPMD trial

Benitec Biopharma announced positive interim results from its BB-301 Phase 1b/2a first-in-human study (NCT06185673) for Oculopharyngeal Muscular Dystrophy, showing a 100% response rate across all treated patients in both low-dose and high-dose cohorts, with high-dose patients showing greater improvements in throat emptying and swallowing capacity at 3 months.

Detected & updated continuously · Source: Nebula